Internal Reference Number: FOI_7990
Date Request Received: 11/06/2024 00:00:00
Date Request Replied To: 04/07/2024 00:00:00
This response was sent via: By Email
Request Summary: Lung cancer
Request Category: Researcher
| Question Number 1: How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab • Atezolizumab Monotherapy • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel • Dabrafenib + Trametinib • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin • Durvalumab • Gemcitabine • Nitedanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab Monotherapy • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) • Pemetrexed + Platinum (Carboplatin/Cisplatin) • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) - 9 • Amivantamab - 0 • Atezolizumab Monotherapy - 8 • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel - less than 5 • Dabrafenib + Trametinib - less than 5 • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin - 0 • Durvalumab - less than 5 • Gemcitabine - less than 5 • Nitedanib + Docetaxel - less than 5 • Nivolumab - 0 • Osimertinib - 17 • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) - less than 5 • Paclitaxel - 0 • Pembrolizumab Monotherapy - 6 • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) - 0 • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) - 9 • Pemetrexed + Platinum (Carboplatin/Cisplatin) - less than 5 • RET Inhibitors (Pralsetinib, Selpercatinib) - 0 • Sotorasib - less than 5 • Tepotinib - 0 • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin - less than 5 • Other active systemic anti-cancer therapy - less than 5 • Palliative care only - unable to answer | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
